Welcome to the March newsletter edition. As spring
begins to brighten the days and warm the weather, our team has been
busy representing the power of iPSCs on the global stage.
This month, we’re excited to share our latest scientific
collaborations, posters, and blogs, as well as highlights from a series
of international conferences, including JSRM in Japan, ADPD in Denmark,
and SOT in California.
Continue reading to discover the exciting developments
that have kept us moving forward throughout March and to learn about
upcoming opportunities to connect with our experts.
Key highlights in March
- PRISM ALS: New stem
cell models could transform research into treatments for MND/ALS
- Advancing sporadic
Alzheimer’s disease research with our sAD iPSC Collection &
Early Access axoCells™ neural stem cells
- New poster: Modeling
ALS with iPSC‑derived motor neurons
- iPSC-derived
cardiomyocytes for drug discovery, research and cardiotoxicity
studies
- New poster: New
Approach Methodologies (NAMs): Assessing cardiotoxicity and
neurotoxicity in vitro using human iPSC-derived cells
- Upcoming webinar:
Application of automated patch clamp for characterization and
screening of axoCells™ hiPSC-derived cardiomyocytes
- Where you can meet the
Axol team
|
|
|
PRISM ALS: New
stem cell models could transform research into treatments for MND/ALS
|
|
|
|
|
We are excited to announce PRISM ALS, a new global
initiative designed to accelerate the discovery of effective treatments
for ALS/MND by improving access to specially grown, patient-derived
stem cell models that better reflect the biological diversity of the
disease.
The collaboration brings together ALS Therapy
Development Institute (ALS TDI), LifeArc, and Axol Bioscience to
develop high-quality iPSC-derived motor neuron models that can be used
to test therapies, inform clinical trial design, and identify distinct
biological subtypes of ALS/MND.
|
|
|
Advancing
sporadic Alzheimer’s disease research with our sAD iPSC Collection
& Early Access axoCells™ neural stem cells
|
|
|
|
|
In partnership with StrataStem, we provide a
comprehensive collection of sporadic Alzheimer’s disease (sAD) iPSC
lines that enable the development of in
vitro models of complex sAD using donor‑specific and
genetically relevant backgrounds for drug discovery and research.
Our Early Access axoCells™ neural stem cells are derived
from patient‑specific iPSCs representing multiple APOE genotypes.
|
|
|
New poster:
Modeling ALS with iPSC‑derived motor neurons
|
|
|
|
|
Our Project Manager, Sian Humphreys, presented our new
poster, “Modeling ALS with iPSC‑derived motor neurons,” at ADPD in
Copenhagen.
- ALS iPSC-derived motor
neurons demonstrate distinct morphology, firing frequency,
and synchronisation patterns when compared to unaffected odnors
- The frequency and
duration of burst firing in motor neurons are modified by the
addition of astrocytes and microglia
|
|
|
iPSC-derived
cardiomyocytes for drug discovery, research and cardiotoxicity studies
|
|
|
|
|
Our highly validated, chamber-specific cardiomyocytes
exhibit distinct atrial or ventricular pharmacology and phenotypes,
generated from both female and male donors.
- Spontaneously beat 3
days post‑thaw and are assay‑ready in just 7 days
- Ventricular
cardiomyocytes are validated against all 28 CiPA compounds
- Atrial cardiomyocytes
show no evidence of endogenous arrhythmias and demonstrate
functional responses to atrial‑specific compounds
|
|
|
New poster:
New Approach Methodologies (NAMs): Assessing cardiotoxicity and
neurotoxicity in vitro
using human iPSC-derived cells
|
|
|
|
|
Our Scientific Group Leader, Jamie Bhagwan, presented
our new poster titled "New poster: New Approach Methodologies
(NAMs): Assessing cardiotoxicity and neurotoxicity in vitro using human
iPSC-derived cells" at SoT in San Diego.
- Chamber-specific human
iPSC-derived cardiomyocytes exhibit distinct baseline
contractility waveforms
- Human iPSC‑derived
sensory neurons' neurite outgrowth is dependent on seeding
density and the timing of compound addition
|
|
|
Upcoming
webinar: Application of automated patch clamp for characterization and
screening of axoCells™ hiPSC-derived cardiomyocytes
|
|
|
|
|
Join us on 21 April at 3:00 PM BST / 4:00 PM CET to
explore how improved metabolic maturation strategies and scalable
automated patch‑clamp workflows can strengthen the translational
relevance, throughput, and reproducibility of cardiac research.
- Part 1: Cardiac chamber
specificity of axoCells™ hiPSC‑derived cardiomyocytes and
metabolic maturation approaches, presented by Dr. Jamie Bhagwan
- Part 2:
Characterization and screening of axoCells™ hiPSC‑derived
cardiomyocytes using automated patch clamp, presented by Dr Kadla
Rosholm
|
|
|
Axol
Bioscience, coming to a conference near you
|
|
|
|
|
Our 2026 conference schedule is filling up fast. Come
and see us if you're attending the following conferences.
|
|
|
Physiologically relevant iPSC-derived models
|
|
|
We use iPSCs to build more relevant models of human
disease to expand your understanding and de-risk drug development.
|
|
|
|
.jpg?width=500&upscale=true&name=PRISM%20ALS%20A%20New%20Global%20Collaboration%20to%20Expand%20Patient-Derived%20Stem%20Cell%20Models%20and%20Accelerate%20Treatments%20%20(1).jpg)
.jpg?width=500&upscale=true&name=iPSC-derived%20cardiomyocytes%20for%20drug%20discovery%2c%20research%20and%20cardiotoxicity%20studies%20(1).jpg)
%20Assessing%20cardiotoxicity%20and%20neurotoxicity%20in%20vitro%20using%20human%20iPSC-derived%20cells.jpg?width=500&upscale=true&name=New%20poster%20New%20Approach%20Methodologies%20(NAMs)%20Assessing%20cardiotoxicity%20and%20neurotoxicity%20in%20vitro%20using%20human%20iPSC-derived%20cells.jpg)
